Generic Tagrisso (Osimertinib 80mg)_Tagrix


US Brand Name:Tagrisso
Generic Name:Osimertinib
Generic Brand Name:Tagrix
Manufacturer:Beacon Pharma 
Packaging:Pack of 30 Tablets


  • CNY: ¥7,695.00


Osimertinib is the first of its kind to be indicated for patients with T790M mutation-positive NSCLC, irrespective of previous treatment with an EGFR tyrosine kinase inhibitor (TKI). Mutations in the EGFR receptor can lead to uncontrolled cell growth and tumour formation. Osimertinib targets both the EGFR mutation that triggers cancer development and T790M, a mutation that makes tumours resistant to existing treatment with EGFR-TKIs. Tagrix is the first global generic preparation of Osimertinib which is approved by Directorate of Drug Administration, Ministry of Health and Family Welfare, People’s Republic of Bangladesh.

Superiority of Tagrix

  1. A potent inhibitor for EGFR mutation (exon 19 & exon 21) and T790M
  2. Only regimen to treat patients with T790M metastatic NSCLC
  3. Can be used as first line treatment for EGFR-mutated Non-Small-Cell Lung Cancer (NSCLC)


There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.